Publication
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
Journal Paper/Review - Jul 5, 2011
Baumann K, Lück H J, Vergote I, Schmalfeldt B, Huober Jens, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U
Units
PubMed
Doi
Citation
Baumann K, Lück H, Vergote I, Schmalfeldt B, Huober J, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 2011; 123:27-32.
Type
Journal Paper/Review (English)
Journal
Gynecol Oncol 2011; 123
Publication Date
Jul 5, 2011
Issn Electronic
1095-6859
Pages
27-32
Brief description/objective
The aim of this study was to select the best catumaxomab regimen for further investigation in ovarian cancer based on confirmed tumour response.